BRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules

Reuters01-08

BRIEF-<a href="https://laohu8.com/S/600196">Shanghai Fosun</a> Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules

Jan 8 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:

DRUG REGISTRATION APPLICATION OF FORITINIB SUCCINATE CAPSULES ACCEPTED BY NMPA

Further company coverage: 600196.SS

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2601035005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-08 18:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601035005","market":"nz","top_or_hot":-1,"title":"BRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/600196\">Shanghai Fosun</a> Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules</title></head><body><p><span>Jan 8 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun Pharmaceutical Group Co Ltd</a> <span>600196.SS</span>:</p><ul><li><p>DRUG REGISTRATION APPLICATION OF FORITINIB SUCCINATE CAPSULES ACCEPTED BY NMPA</p></li></ul><p>Further company coverage: <span>600196.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-08 18:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/600196\">Shanghai Fosun</a> Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate Capsules</title></head><body><p><span>Jan 8 (Reuters)</span><span> - </span><a href=\"https://laohu8.com/S/SFOSF\">Shanghai Fosun Pharmaceutical Group Co Ltd</a> <span>600196.SS</span>:</p><ul><li><p>DRUG REGISTRATION APPLICATION OF FORITINIB SUCCINATE CAPSULES ACCEPTED BY NMPA</p></li></ul><p>Further company coverage: <span>600196.SS</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0175","symbol_name":"白马股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nFWN3Y81OO:1","article_id":"2601035005","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601035005","pubTimestamp":1767867975,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate CapsulesJan 8  - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:DRUG REGISTRATION APPLICATION OF FORITINIB SUCCINATE CAPSULES ACCEPTED BY NMPAFurther company coverage: 600196.SS ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600196":"复星医药","BK0175":"白马股","BK0196":"行业龙头","BK0060":"抗癌","BK0096":"民营医院","BK0187":"一线龙头","BK0239":"医药制造","BK0028":"国家队","BK0183":"MSCI概念","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"简报-上海复星医药称NMPA受理琥珀酸福瑞替尼胶囊注册申请","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600196":0.9},"content_text":"BRIEF-Shanghai Fosun Pharma Says NMPA Accepted Registration Application Of Foritinib Succinate CapsulesJan 8 (Reuters) - Shanghai Fosun Pharmaceutical Group Co Ltd 600196.SS:DRUG REGISTRATION APPLICATION OF FORITINIB SUCCINATE CAPSULES ACCEPTED BY NMPAFurther company coverage: 600196.SS ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2601035005","isCrawlerRequest":true}